comprehensive -WSS

comprehensive

author：leisure time 2025-10-02 19:21:08 - browse：58

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

The Food and Drug Administration rejected an Alnylam Pharmaceuticals’ therapy for an increasingly prevalent heart disease, the company said Monday, citing insufficient evidence that the treatment meaningfully improved patients’ lives.

Alnylam will no longer seek approval of its drug, an intravenous medicine sold as Onpattro, for people with ATTR-CM, a progressive disease that leads to heart failure if left untreated. The company is in the late stages of development of an updated version of Onpattro that can be administered through a small needle under the skin. Data from a pivotal study, expected next year, would support an FDA application for that treatment.

For Onpattro, a 12-month clinical trial found that the treatment outperformed placebo on a test of how far patients could walk over the course of six minutes, suggesting the medicine slowed down the progression of ATTR-CM. Onpattro also improved patients’ scores on a quality-of-life questionnaire compared to placebo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： ProMED, early warning system on disease outbreaks, in peril

hotspot

WSS

Dramatically reducing cancer deaths requires the PASTEUR Act

ProMED, early warning system on disease outbreaks, in peril

What the cancer research community can learn from the Covid response

Verily hires former Apple Health leader as chief scientific officer

Biden calls for immediate release of Niger's president amid apparent coup

Mega Millions jackpot rises to record $1.55 billion for Tuesday's drawing

hotspot

comprehensive

entertainment

Guidelines to prevent youth baseball injuries need more muscle

Treeline, Josh Bilenker's next biotech, is cloaked in mystery

Supreme Court strikes down use of affirmative action

What the cancer research community can learn from the Covid response

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Microsoft strikes partnership with Duke Health to advance health AI

Medical records are filled with copy

Nearly two

Bright Health sells Medicare Advantage business to Molina

'Ancient DNA,' 23andMe reveal African American ancestries

hotspot

What Henrietta Lacks settlement says about racism in medicine

OTC birth control: A brief history of over the counter pill design

For BCIs, commercial hurdles may be bigger than scientific ones

A cyberattack has disrupted hospitals and health care in several states

Verily hires former Apple Health leader as chief scientific officer

Nearly two

explore

hotspot

hotspot

hotspot